Treatment of Acute Ischemic Stroke with Intravenous Urokinase (TASK-UK): Protocol for a Multicenter, Prospective, Real-World Study.
Yongli Tao, Hui Fang, Lulu Pei...
https://pubmed.ncbi.nlm.nih.gov/42570202/Actively Recruiting
Led by The First Affiliated Hospital of Zhengzhou University · Updated on 2024-01-08
1800
Participants Needed
16
Research Sites
56 weeks
Total Duration
Researchers are comparing the safety and effectiveness of two intravenous drugs, urokinase and alteplase, in treating acute ischemic stroke AIS within 6 hours of symptom onset. Alteplase is currently recommended within 4.5 hours but is costly, while urokinase is less expensive. Existing studies show mixed results for urokinase, so this study aims to gather real-world data on both treatments, including safety, effectiveness, and economic impact, to help inform future stroke care. The study involves patients receiving either intravenous urokinase or alteplase as treatment for AIS. Researchers will observe and analyze these treatments in multiple centers across the nation, comparing outcomes and exploring different urokinase dosages and related risk factors. Alteplase serves as the active control group to evaluate urokinase against current standards. Participants will be monitored for their functional recovery using the modified Rankin scale at 90 days after treatment to assess good outcomes. The study includes clinical diagnosis confirmation, imaging to exclude hemorrhage, and patient consent procedures. Data on safety, effectiveness, and costs will be collected, with follow-up assessments at day 90. The trial aims to provide comprehensive information over its duration until December 2026.
CONDITIONS
Treatment of Acute Ischemic StroKe With Intravenous UroKinase Real-world Research: a Multicenter, Prospective Study
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The First Affiliated Hospital of Zhengzhou University
Lead Sponsor
Techpool Bio-Pharma Co., Ltd.
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 4.5 hours from symptom onset
Participants receive intravenous urokinase or alteplase as part of their acute ischemic stroke treatment.
1 treatment visit (in-person)
Duration - Approximately 90 days
Participants are observed to assess effectiveness, safety, and functional outcomes after treatment.
Follow-up visits up to day 90
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Yongli Tao, Hui Fang, Lulu Pei...
https://pubmed.ncbi.nlm.nih.gov/42570202/The First Affiliated Hospital of Zhengzhou University
Lead Sponsor
Techpool Bio-Pharma Co., Ltd.
Collaborating Sponsor